Mergers & Acquisitions ·
DOJ and FTC grant early termination of HSR waiting period for Lifecore Inc. merger
LFCRLifecore Biomedical, Inc. de
The Department of Justice and the Federal Trade Commission granted early termination of the statutory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act on November 4, 2026. This action satisfies a key closing condition for the previously announced merger between Lifecore Biomedical, Inc. and its parent company, Lifecore Inc., which involves the merger of a subsidiary into the Company with the Company surviving as a wholly owned subsidiary. The transaction remains subject to remaining closing conditions, including stockholder approval at a special meeting. Lifecore Biomedical develops medical devices for hemostasis and tissue repair.